← Back to Clinical Trials
Recruiting NCT06807684

NCT06807684 Abnormal Connectivity Involving the Social Reciprocity Network in Autism and the Impact of Neurostimulation in Mitigating the Abnormalities

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06807684
Status Recruiting
Phase
Sponsor Christiana Care Health Services
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 12 participants
Start Date 2024-08-15
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 13 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
transcranial magnetic stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 12 participants in total. It began in 2024-08-15 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

There is no consensus regarding the neurological substrate underpinning ASD. The investigators describe the novel concept of "social reciprocity network" and hypothesize that aberrant connectivity/oscillatory patterns affecting this network contribute to the core deficits in ASD. The overarching goal of this trial is to explore abnormalities involving the neuronal connectivity and oscillatory patterns within the social reciprocity network and to elucidate the role of modulating this network via rTMS in improving the above measures and social cognition in ASD. Quantitative electroencephalography (QEEG) coherence and spectral power analysis are reliable measures of neuronal connectivity and dynamics. The investigators aim to study the QEEG coherence/spectral power analysis to explore the neuronal dynamics affecting the social reciprocity network in ASD.

Eligibility Criteria

Inclusion criteria 1\. Fulfilling the DSM-V criteria for ASD and confirmed by CARS2, HF Exclusion criteria 1. Patients with ASD exhibiting significant anxiety or contact avoidance, precluding them from cooperating with the procedure 2. Patients with a known diagnosis of seizures 3. Presence of any metallic implants or devices in the head or neck area 4. Pregnant women

Contact & Investigator

Central Contact

Mitra Assadi, MD

✉ mitra.assadi@christianacare.org

📞 3026233017

Frequently Asked Questions

Who can join the NCT06807684 clinical trial?

This trial is open to participants of all sexes, aged 13 Years or older, up to 18 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06807684 currently recruiting?

Yes, NCT06807684 is actively recruiting participants. Contact the research team at mitra.assadi@christianacare.org for enrollment information.

Where is the NCT06807684 trial being conducted?

This trial is being conducted at Newark, United States.

Who is sponsoring the NCT06807684 clinical trial?

NCT06807684 is sponsored by Christiana Care Health Services. The trial plans to enroll 12 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology